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Sleep loss is both common and critically relevant to our society and might lead to the abuse of psychostimulants such as
amphetamines, cocaine and modafinil. Since psychoactive substance abuse often occurs within a scenario of sleep deficit, the
purpose of this investigation was to compare the sleep patterns of rats challenged with cocaine (7 mg/kg, ip), methamphetamine
(7 mg/kg, ip), or modafinil (100 mg/kg, ip) subsequent to paradoxical sleep deprivation (PSD) for 96 h. Our results show that,
immediately after 96 h of PSD, rats (10 per group) that were injected with a psychostimulant presented lower percentages of
paradoxical sleep compared to those injected with saline (P < 0.01). Regarding slow wave sleep (SWS), rats injected with
psychostimulants after PSD presented a late rebound (on the second night subsequent to the injection) in the percentage of this
phase of sleep when compared to PSD rats injected with saline (P < 0.05). In addition, the current study has produced evidence
of the characteristic effect of each drug on sleep architecture. Home cage control rats injected with modafinil and methamphet-
amine showed a reduction in SWS compared with the saline group. Methamphetamine affected sleep patterns most, since it
significantly reduced paradoxical sleep, SWS and sleep efficiency before and after PSD compared to control (P < 0.05). Cocaine
was the psychostimulant causing the least changes in sleep pattern in relation to those observed after saline injection. Therefore,
our results suggest that abuse of these psychostimulants in a PSD paradigm aggravates their impact on sleep patterns.
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INTRODUCTION
Despite the side effects of psychostimulant drugs (PD)
in medical and psychiatric co-morbidity, illicit PD are broadly
disseminated as an aid used by shift workers to counter
discomfort in their schedules. PD lead to various physi-
ologic effects, including hormonal (1), behavioral (2,3) and
neurochemical (4) changes. Nevertheless, the problems
most frequently reported by PD users are sleep distur-
bances (5).
PD have acute and chronic effects on sleep architec-
ture. Difficulty in initiating and maintaining sleep as well as
lower sleep efficiency (SE) and significant sleep onset
delay are common amongst cocaine users (6). Further-
more, in cocaine-dependent individuals, alterations in ob-
jective sleep quality accompany their characteristic binge-
abstinence cycle (7). PD abusers often have increased
propensity for rapid eye movement (REM) sleep during
periods of acute and subacute withdrawal from cocaine
and amphetamine (8). Indeed, studies on these signs and
symptoms have reported that they may reflect a state of
relative functional dopamine (DA) depletion in the brain
during abstinence (8).
A recent study using microdialysis coupled with elec-
trophysiologic recordings reported an increase in DA
concentration during wakefulness and paradoxical sleep
(PS) compared to that during slow wave sleep (SWS) (9).
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Also reported was an increased neural activity of ventral
tegmental area neurons during PS (10) and a recent study
showed that mice with profound DA depletion display a
complete suppression of REM sleep (4). Indeed, paradoxi-
cal sleep deprivation (PSD) appears to enhance DA concen-
trations and DA receptor sensitivity (11,12) and these alter-
ations may be attributable to DA postsynaptic receptor su-
persensitivity (11,13) and DA transporter (DAT) subsensitiv-
ity (11,14). The recovery period after PSD is marked by an
increased pressure of REM sleep (15) and plays a role in
restoring the function of the catecholaminergic system (16).
PD abuse often occurs within a PSD scenario, the main
effect of these drugs being on the dopaminergic system
(17). Internationally, amphetamine-type stimulants and
cocaine are among the three most common substances of
abuse (18).
Cocaine primarily inhibits DAT (19) by causing a marked
increase in the synaptic cleft of striatal DA concentrations.
Amphetamines are far more effective in binding DAT than
cocaine, promoting a greater DA release (20). Amphet-
amines release DA only in cells that express DAT (21);
however, the release is greater for cells that co-express
vesicular monoamine transporter (VMAT). This indicates
that both plasmalemmal and vesicular components are
involved in the DA-releasing action of amphetamines, VMAT
sequesters intraneuronal DA into vesicles for storage and
subsequent release, and thus is an important regulator of
cytolasmic DA concentrations and dopaminergic function.
Cells that co-express DAT and VMAT have a higher capac-
ity to retain accumulated DA by means of their vesicles,
whereas the cytoplasmic pool of DA, the only one present
in DAT cells, is more easily washed out by superfusion
(22). The larger absolute amount of DA released by am-
phetamine from DAT/VMAT cells compared with DAT cells
may be due to direct mobilization of VMAT and/or ex-
change diffusion from a cytoplasmic pool that is, to a
certain extent, fed by DA leaking out of the vesicles and is
therefore not as easily exhausted as in DAT cells (22).
Due to the undesired behavioral and cognitive effects
observed after the use of psychostimulants like cocaine
and methamphetamine, an alternative non-illicit drug that
promotes wakefulness named modafinil has been ap-
proved by the Food and Drug Administration. This drug has
been largely used to treat excessive daytime sleepiness
and is characterized by not causing rebound hypersomno-
lence (23). Pharmacological evidence is unclear, but some
investigators suggest that modafinil acts through competi-
tive binding to DAT (24) and provokes a surge of extracel-
lular DA concentration (17,25). Although dopaminergic
transmission is an attractive therapeutic approach, there is
considerable pharmacological evidence that modafinil acts
through noradrenergic mechanisms to promote wakeful-
ness (26,27).
Since PSD plays a crucial role in the dopaminergic
system, and substances that increase the release of DA are
commonly psychostimulants, the aim of the present study
was to compare the sleep patterns of rats challenged with
different wake-promoting drugs subsequent to 96 h of PSD.
MATERIAL AND METHODS
Animals
Three-month-old male Wistar rats bred in our facilities
(~300 g) were used in this experimental protocol. The
animals were maintained at 22 ± 1°C on a 12/12-h light/
dark cycle (lights on at 7:00 am), with free access to food
and water. The research protocol was approved by the
local UNIFESP Ethics Committee (CEP No. 482/02).
Surgical preparation
The rats were anesthetized with ketamine hydrochlo-
ride and diazepam (90 and 4.5 mg/kg body weight, ip).
After full induction of anesthesia, the animals were mounted
in a stereotaxic frame and their body temperature was
maintained at 36.5-37°C with a homeothermic blanket. To
record the cortical electrocorticogram (ECoG), two pairs of
screw electrodes were inserted through the skull ipsilater-
ally: 1 mm posterior to the bregma, 3 mm lateral to the
central suture, and 1 mm anterior to lambda, 4 mm lateral
to the central suture. Electromyogram (EMG) electrodes
were implanted in the neck muscles, soldered to a 6-pin
socket and covered with dental acrylic cement. After sur-
gery, the rats were individually placed in transparent plas-
tic cages and allowed a 14-day period of recovery from
surgery comprising 10 days without the recording cable
followed by a 3-day adaptation period with the polysom-
nography cable connected.
Sleep recording
Electrophysiological signals were recorded on a digital
polygraph (Neurofax QP 223 A® Nihon Kohden, Tokyo,
Japan) at a sampling rate of 200 Hz. Recordings were
visually scored for 30-s epochs according to classical
sleep-waking criteria as reflected either in i) the waking
state, which is characterized by low voltage, fast ECoG
and high EMG activity; ii) SWS, characterized by continu-
ous high amplitude, slow ECoG activity and low EMG
activity, or iii) PS, characterized by high ECoG activity and
absence of EMG activity. Each 30-s epoch was defined by
the wave pattern (waking state, SWS, PS), which occupied
more than 50% of the time. When artifacts or noise did not
allow characterization of an epoch, assessments were
made based on immediate surrounding epochs. Animals
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were habituated to the recording system before the re-
bound recording was performed.
Paradoxical sleep deprivation
The PSD method consists of placing 10 animals inside
a tiled tank (123 x 44 x 44 cm) containing 14 narrow circular
platforms (6.5 cm in diameter) filled with water to within 1
cm of the upper surface of the platform. Such arrangement
allows the animals to move around by leaping from one
platform to another. One tank was used for each group. In
this procedure when an animal reaches PS, the accompa-
nying muscle atonia causes it to touch the water and wake
up. Under these conditions, the procedure causes a com-
plete loss of PS on each of the 4 days (27). Food and water
were provided ad libitum by placing chow pellets and water
bottles on a grid located on the top of the tank. The water in
the tank was changed daily throughout the 96-h period of
PSD.
Groups
After the PSD period, the rats were randomly distrib-
uted into 8 experimental groups of 10 animals each: saline
(SAL) home cage and PSD, cocaine (COC, 7 mg/kg, ip)
home cage and PSD, methamphetamine (METH, 7 mg/kg,
ip) home cage and PSD, or modafinil (MOD, 100 mg/kg, ip)
home cage and PSD (as depicted in Figure 1).
Drugs
The doses of each drug were chosen on the basis of
previous studies and prepared immediately prior to testing
by dissolving in distilled water. Systemic injections were
administered ip in a volume of 1 mL/kg: METH (7 mg/kg, ip)
(28), COC (7 mg/kg, ip; Sigma, St. Louis, MO, USA) (2), and
MOD (100 mg/kg, ip; Laboratoire L. Lafon, France) (29).
Statistical analysis
Two-way analysis of variance (ANOVA) was used to
analyze group differences (treatment/sleep condition),
period recordings and interaction between these two fac-
tors. For specific group comparisons, the post hoc Duncan
test was performed and values are reported as means ±
SEM, with the level of significance set at P < 0.05.
RESULTS
Effects of drug treatment on basal sleep values
Sleep efficiency. Light period: ANOVA revealed a sig-
nificant effect of group (F(7,61) = 24.51; P < 0.01), time-
points (F(1,61) = 11.45; P < 0.01) and an interaction effect
between these factors (F(7,61) = 25.74; P < 0.01). Rats
injected with METH presented lower percentages of SE on
the first day of recording (D1) than rats injected with SAL,
Figure 1. Schematic representation of the groups studied (panel
A) and the protocol (panel B). Each group contained 10 rats
which received saline, cocaine (7 mg/kg, ip), methamphetamine
(7 mg/kg, ip), or modafinil (100 mg/kg, ip). L = light period; D =
dark period; PSD = paradoxical sleep-deprived rats.
COC, and MOD (P < 0.01). On the second day of recording
(D2), METH rats showed a significant increase in the
percentages of SE compared with MOD animals (P <
0.01). The administration of MOD resulted in a statistical
decrease of SE in relation to the SAL and COC groups at
D2 (P < 0.01; Figure 2). Dark period: Statistically signifi-
cant differences were detected for groups (F(7,61) = 24.51; P
< 0.01) and time points (F(1,61) = 11.45; P < 0.01) as was an
interaction effect between these factors (F(7,61) = 25.74; P <
0.01). Post hoc analysis revealed a significant increase of
SE in the METH group compared to SAL, COC (P < 0.05),
and MOD (P < 0.01 on day 1) at both D1 and D2.
Slow wave sleep. Light period: Statistically significant
differences were detected for group (F(7,61) = 24.51; P <
0.01) and time points (F(1,61) = 11.45; P < 0.01) and an
interaction effect between these factors (F(7,61) = 25.74; P <
0.01) was verified. Acute administration of METH induced
a significant decrease in SWS compared with the SAL,
COC, and MOD groups (P < 0.01) at D1. In contrast, at D2,
rats injected with METH presented higher percentages of
SWS compared with MOD rats (P < 0.05). The acute
administration of MOD induced an increase of SWS com-
pared with the SAL group and a decrease when compared
with COC rats at D2 (P < 0.05), as shown in Figure 2. Dark
period: Statistically significant differences were detected
in groups (F(7,61) = 24.51; P < 0.01) and time points (F(1,61) =
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Figure 2. Percentage of each sleep parameter (sleep efficiency, SE; slow wave sleep, SWS, and paradoxical sleep, PS) observed
during the light (left panels) and dark periods (right panels) in home cage rats challenged with saline (SAL), cocaine (COC, 7 mg/kg,
ip), methamphetamine (METH, 7 mg/kg, ip) and modafinil (MOD, 100 mg/kg, ip) during two days of recording (D1 = open column and
D2 = filled column). Data are reported as means ± SEM. #P < 0.05 compared to the saline group; *P < 0.05 compared to the group
challenged with cocaine; +P < 0.05 compared to the group challenged with modafinil (ANOVA followed by the Duncan test).
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11.45; P < 0.01). During the dark period, METH increased
SWS when compared to the SAL group (P < 0.01) at D1.
No statistically significant differences were observed in the
remaining non-PSD groups (Figure 2).
Paradoxical sleep. Light period: As shown in Figure 2,
the main effect of group (F(7,61) = 39.6; P < 0.01), time points
(F(1,61) = 75.74; P < 0.01) and interaction between group
and rebound recordings (F(7,61) = 36.44; P < 0.01) were
observed. Rats injected with METH had lower percent-
ages of PS at D1 when compared with all other groups (P
< 0.05). Dark period: There were no statistically significant
differences in the dark period.
Effects of drug challenge after paradoxical sleep
deprivation
Saline. Light period: In the PSD group SE was signifi-
cantly higher and SWS lower on the first day of rebound
(R1) when compared with the non-PSD group recordings
(P < 0.01). Regarding SWS, the percentages of this stage
were significantly higher on the second day of rebound
(R2) in relation to R1 for the PSD group. PSD resulted in a
marked increase of PS at R1 (P < 0.01) that persisted until
R2 in SAL-injected rats (P < 0.01), as shown in Figure 3.
Dark period: The Duncan test showed that, after PSD, rats
injected with SAL presented increased percentages of SE,
SWS and PS compared to the non-PSD group at D1 (P <
0.01). However, at R2, these percentages were not differ-
ent from control and were significantly lower than R1 (P <
0.05).
Cocaine. Light period: After PSD, rats injected with
COC presented a significant increase of SE at R1 when
compared with the non-PSD group (P < 0.01). The per-
centages of SWS at D2/R2 were significantly higher than
at D1/R1 in both the PSD and non-PSD groups (P < 0.05).
PSD resulted in a marked increase of PS at R1 (P < 0.01)
that persisted until R2 in COC-injected rats (P < 0.01), as
shown in Figure 3. Dark period: The Duncan test showed
that, after PSD, rats injected with COC presented in-
creased percentages of SE and PS compared to the non-
PSD group at R1 and R2 (P < 0.01). However, at R2, these
percentages were significantly lower than at R1 (P < 0.05).
Methamphetamine. Light period: The Duncan test re-
vealed that METH was the only drug that promoted signifi-
cant differences between D1 and D2 in SE, SWS and PS in
the non-PSD groups (P < 0.01). After PSD, rats injected
with METH presented a decrease in SWS at R1 that
persisted until R2 compared with the non-PSD group (P <
0.01). However, when these days were compared, R2 was
found to be significantly higher than R1. Indeed, this drug
promoted an increase of PS at R1 when compared with the
non-PSD group (P < 0.01). Dark period: After PSD, rats
presented increased percentages of SE compared to the
non-PSD group at R1 (P < 0.01). At R2, the percentages of
SE and PS were significantly lower at R2 compared with
R1 (P < 0.05), as shown in Figure 3.
Modafinil. Light period: After the administration of MOD,
SE and SWS were significantly reduced at R2 when com-
pared to R1 in non-PSD rats (P < 0.05). After PSD, SE and
PS were significantly higher at R1 and R2 when compared
with the respective non-PSD group recordings (P < 0.01).
PSD rats presented less PS at R2 compared with R1 (P <
0.05). PSD promoted an initial decrease of the SWS phase
at R1 and an increase at R2 compared with the non-PSD
group (P < 0.05). In this sleep stage, PSD rats presented
higher percentages at R2 compared with R1, as shown in
Figure 3. Dark period : The Duncan test showed that, after
PSD, rats injected with MOD presented increased percent-
ages of SE, SWS and PS compared to the non-PSD group
at R1 and R2 (P < 0.01). The percentages of SE and PS
were significantly lower at R2 than at R1 (P < 0.05).
Comparisons among psychostimulant drugs after
paradoxical sleep deprivation
Sleep efficiency. Light period: The PSD + METH group
had significantly lower SE at both R1 and R2 compared
with the SAL sleep-deprived group and with the rats chal-
lenged with COC and MOD (P < 0.01), as shown in Figure
4. Dark period: At R1, METH resulted in a statistical
increase in SE in PSD rats compared with rats challenged
with MOD (P < 0.01), COC (P < 0.05) and SAL (P < 0.01).
At R2, the PSD + METH group presented a significant
increase in SE compared to the PSD + SAL (P < 0.01)
group. On both rebound days, MOD led to a significant
increase in sleep time compared to SAL-challenged rats (P
< 0.01), as shown in Figure 4.
Slow wave sleep. Light period: Comparison between
the PSD groups indicated that on the first day after sleep
deprivation PSD + METH produced significantly less SWS
than PSD + SAL, PSD + COC and PSD + MOD (P < 0.01).
At R2, rats injected with METH presented lower percent-
ages of SWS compared with rats injected with COC (P <
0.05). Indeed, the acute administration of MOD induced an
increase of SWS compared with the SAL group at R1 (P <
0.05), as shown in Figure 4. Dark period: Rats injected with
COC (P < 0.05), METH (P < 0.01) and MOD (P < 0.01) had
more SWS compared with PSD + SAL rats at R2 (P < 0.01).
Paradoxical sleep. Light period: After PSD, rats in-
jected with COC, METH and MOD presented a significant
reduction of PS compared to SAL, and this reduction
persisted until the second day in the METH group (P <
0.01). The Duncan test showed that at R1 this sleep stage
was significantly reduced in the MOD-challenged group
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Figure 3. Percentage of each sleep parameter (sleep efficiency, SE; slow wave sleep, SWS, and paradoxical sleep, PS) observed
during the light (left panels) and dark (right panels) periods in home cage and paradoxical sleep-deprived (PSD) rats challenged with
saline (SAL), cocaine (COC, 7 mg/kg, ip), methamphetamine (METH, 7 mg/kg, ip), and modafinil (MOD, 100 mg/kg, ip) during 2 days
of recording (home cage group-D1/D2; PSD group-R1/R2). Data are reported as means ± SEM. +P < 0.05 compared to the first day
of sleep recording; *P < 0.05 compared to the non-sleep-deprived group (ANOVA followed by the Duncan test).
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when compared with the PSD + COC group (P < 0.05).
Indeed, in both R1 and R2, PSD + METH differed from PSD
+ COC and PSD + MOD (P < 0.01). The reduction was due
to the lower number of PS episodes in these groups
compared to the others (P < 0.01; data not shown). Dark
period: The groups challenged with psychostimulants pre-
sented an increase of PS compared to the PSD + SAL at
R1 (P < 0.01) and this increase was observed even at R2
Figure 4. Percentage of each sleep parameter (sleep efficiency, SE; slow wave sleep, SWS, and paradoxical sleep, PS) during the
light (left panels) and dark (right panels)  periods in paradoxical sleep-deprived rats (PSD) challenged with saline (SAL), cocaine
(COC, 7 mg/kg, ip), methamphetamine (METH, 7 mg/kg, ip) and modafinil (MOD, 100 mg/kg, ip) during two days of recording of PSD
recovery (R1/R2). Data are reported as means ± SEM. #Different from the group challenged with saline; *different from the group
challenged with cocaine; +different from the group challenged with modafinil (ANOVA followed by Duncan test, see text for P values).
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after MOD administration. Indeed, at R1, rats injected with
METH presented more PS that those injected with COC (P
< 0.05), as shown in Figure 4.
DISCUSSION
The psychostimulants investigated in the current study
induced different patterns of sleep-wake cycle alterations
due to the effect of the drugs themselves and to their
association with PSD. Our results show that immediately
after 96 h of PSD, rats injected with psychostimulants
presented lower percentages of PS when compared to
those injected with SAL solution but, regarding SWS, after
PSD rats injected with the three drugs showed a late
rebound (on the second night after the injection) when
compared to PSD + SAL rats. Among the drugs investi-
gated, METH was the one that most affected sleep pat-
terns since it significantly reduced PS, SWS and SE before
and after PSD when compared with the respective SAL
groups during the light period. Indeed, the four groups
presented a significant increase in PS after PSD, but
METH was the only drug capable of inhibiting PS rebound
on the second day after administration.
Psychostimulant drugs such as amphetamines or co-
caine, which facilitate catecholamine release and/or block
their uptake, are commonly used for psychostimulation. D1
and D2 DA receptors are clearly implicated in the induction
of hyperarousal (30) and it has been suggested that presyn-
aptic activation of DA transmission is a key pharmacologic
property mediating the wake-promoting effects of stimu-
lants (31). The immediate reduction in the percentage of
PS observed subsequent to the injection of METH, COC
and MOD when compared to the PSD + SAL group may
have been due to a complex relationship between brain
dopaminergic and noradrenergic signaling systems: DA is
the precursor of noradrenaline and could be a synergic
ligand and a substrate for noradrenergic receptors (32).
Interactions between these systems have hampered at-
tempts to elucidate the exact target for the effects of
stimulant drugs. Like PS, psychostimulants are character-
ized by their property of increasing mesolimbic DA neu-
rons (9). Accordingly, rats submitted to PSD for 96 h
presented supersensitivity of the postsynaptic D2 receptor
(13) and subsensitivity of the presynaptic DAT (14).
The neurotransmitter alterations observed after PSD
suggest that the loss of PS reduces the release of DA by
neurons. The present data show that rats injected with
psychostimulants after PSD presented less PS immedi-
ately after the administration of the drugs when compared
to rats injected with SAL solution, and this was most likely
due to the stimulating effects of the drugs. However, during
the subsequent dark period, rats injected with COC, METH
and MOD presented increased PS compared to the SAL
group. These results suggest that, although the rat is more
active during the dark period, the excess DA released after
administration of the psychostimulants could have caused
a late increase of PS in the drug groups in relation to the
vehicle group. If PSD promotes neurotransmitter changes
that enhance the psychostimulant effects, the combination
of these two variables would promote a powerful wakeful-
ness effect.
In general, PS is more sensitive than SWS to disruption
by manipulation of catecholaminergic transmission (33,34).
Our data show that, although acute COC and MOD admin-
istration to home cage groups had no immediate effect on
SWS, the PSD groups presented a significant increase in
SWS percentages compared to PSD + SAL-challenged
rats. Indeed, after PSD, rats in the psychostimulant groups
presented longer SWS than the SAL group during the
second dark period after PSD. MOD promoted an immedi-
ate reduction in SWS in relation to the respective home
cage group, followed by an exacerbated stimulatory effect
subsequent to PSD, whereas no changes were observed
in the COC group. In contrast to these processes which are
increased by psychostimulants, SWS is accompanied by a
reduction of catecholamine release (35). The prolonged
effects of MOD on SWS may be attributed to its long half-
life and in particular to noradrenergic transmission, since
noradrenaline is a relevant regulating agent for sleep-state
timing (36,37).
After PSD, the METH group showed a significant re-
duction in SWS when compared to the other groups in the
same sleep condition. In contrast, rats injected with COC
and MOD presented higher percentages of SWS com-
pared with the SAL and METH groups. Unlike the COC and
MOD groups, and within just the first 12 h, the home cage
and PSD groups injected with METH had a significant
decrease in the light period of SWS compared with the SAL
group. The reduction observed in this phase may have
been due to the inactivation of the DA system by the drugs,
so that the mechanism of action of a high METH dose
would remain effective even after a prolonged period of
PSD.
It is during the light period of SWS that rat sleep
becomes concentrated and a rebound period of this sleep
phase was observed during the subsequent dark and light
periods. On the basis of these results, we suggest that the
modulation of the sleep-wake response could depend on
the monoaminergic system, mainly if the dopaminergic
system is involved. Since the alterations in dopaminergic
pathways resulting from PSD are mainly marked by in-
creased D1 (38) and D2 (14) receptors and reduced DAT
(responsible for the release and reuptake of DA from within
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the synaptic cleft) the most likely scenario is that dopamin-
ergic drugs that lead to the release of DA, such as amphet-
amine, entail an increase in DA availability after PSD.
Recently, our group published that the PSD method
applied in the present study completely abolishes PS
during the deprivation period (39). After 96 h of PSD, both
female (Antunes IB, Andersen ML, Baracat EC, Tufik S,
unpublished results) and male (39) rats presented signifi-
cantly increased PS percentages. Our data corroborate
with these previous studies showing that all groups pre-
sented rebound of PS after PSD. Indeed, the group in-
jected with METH was the only where loss of PS did not
persist until R2, suggesting that this psychostimulant ex-
erts marked long-term effects in sleep patterns. SE ob-
served during the second dark period was significantly
lower than during the first, indicating a normalized sleep
pattern. After 96 h of PSD, the COC and MOD challenge
caused a significant reduction in PS compared with the
PSD + SAL group which may have been due to the modu-
lation of pharmacological interaction since the sleep-wake
cycle needs more time to regulate the equilibrium of basal
sleep.
Our findings demonstrate that the different pharmaco-
logical profiles of COC, METH and MOD lead to sleep
rebound after PSD. Overall, although the precise mechan-
isms underlying sleep rebound remain obscure, our data
suggest that its function is to enhance sleep recovery by
restoring the physiological and functional concentrations
of catecholaminergic neurons.
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